Journals / Turkish Journal of Medical Sciences / 2009 / Cilt: 39 - Sayı: 2

Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection

Pages
173–177
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies.
📊
Key Findings & Data:Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg stimulation while none of the controls did (P < 0.05).
💡
Conclusion & Impact:Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:HBV vaccination · long-term protection · booster dose requirement

Abstract

Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated. Materials and Methods: Seventeen individuals vaccinated previously were enrolled in the study. They had once developed a protective level of anti-HBs antibody after immunization and their anti-HBs titer had declined to an underprotective level. Twenty uninfected and unvaccinated healthy people were chosen as controls. Lymphoproliferative response to in-vitro stimulation with hepatitis B surface antigen (HBsAg) and anti-HBs response to vaccine were evaluated for immune response. Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg stimulation while none of the controls did (P < 0.05). In all subjects in the study group, anti-HBs response (>= 10 mIU/ml) was detected 1 to 7 days after the booster injection but in only 2 of the controls antibody response was detected 28 days after the first dose of HBV vaccine (P < 0.0001). Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.

Özet

Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated. Materials and Methods: Seventeen individuals vaccinated previously were enrolled in the study. They had once developed a protective level of anti-HBs antibody after immunization and their anti-HBs titer had declined to an underprotective level. Twenty uninfected and unvaccinated healthy people were chosen as controls. Lymphoproliferative response to in-vitro stimulation with hepatitis B surface antigen (HBsAg) and anti-HBs response to vaccine were evaluated for immune response. Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg stimulation while none of the controls did (P < 0.05). In all subjects in the study group, anti-HBs response (>= 10 mIU/ml) was detected 1 to 7 days after the booster injection but in only 2 of the controls antibody response was detected 28 days after the first dose of HBV vaccine (P < 0.0001). Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.

🔖

Cite This Article

KISA, Ü., AVCI, İ. Y., SAYGUN, O., EYİGÜN, C. P., PAHSA, A. (2022). Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection. Turkish Journal of Medical Sciences, Cilt: 39 - Sayı: 2, 173–177. https://ajindex.com/articles/611657

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45. 2. Thiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature Coursaget P, Leboulleux D, Soumare M. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. Lancet 1994; 21: 250-4.
  2. Hadler SC, Coleman PJ, O’Malley P, Judson FN, Altman N. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. Viral Hepatitis and Liver Disease, (Eds) Hollinger FB, Lemon SM, Margolis HS, Williams and Wilkins, Baltimore, 1991, 766-768.
  3. Hwang LY, Lee CY, Beasley RP. Five-year follow-up of HBV vaccination with plasma-derived vaccine in neonates: evaluation of immunogenicity and efficacy against perinatal transmission. Viral Hepatitis and Liver Disease, (Eds) Hollinger FB, Lemon SM, Margolis HS, Williams and Wilkins, Baltimore, 1991, 759-761.
  4. West DJ, Calandra GB: Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019-25. West DJ. Immunologic memory and hepatitis B immunization. Proceedings of the IX Triennial International Symposium on Viral Hepatitis and Liver Disease (Abs), (Eds) Rizzetto M, Purcell RH, Gerin JL, Verme G, Edizioni Minerva Medica pp: 673-674, 1997.
  5. Eyigün CP, Yılmaz S, Gül C, Şengül A, Hacıbektaşoğlu A, Van Thiel DH. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults. Journal of Viral Hepatitis 1998; 5: 265-69. European Consensus Group on Hepatitis B immunity: Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-5.
  6. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long- term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999; 29: 954-9.
  7. Leroux G, Van Hecke E, Michielson W, Voet P, Hauser P, Petre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunisation with hepatitis B surfage antigen (HBsAg) vaccines. Vaccine 1994; 12: 812-8.
  8. Nagaraju K, Naik SR, Naik S. Lack of in vitro lymphoproliferative response to hepatitis B surface antigen in healthy vaccine recipients. Indian J Med Res 1998; 108: 80-4.
  9. Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. Journal of Medical Virology 1998; 24: 377-84.
  10. Krugman S, Davidson M. Hepatitis B vaccine: prospects for durati